Activation of mitogen-and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins

Oncogene

Volumn 33, Issue 12, 2014, Pages 1570-1580

  Reyes, D ^a,b   Ballare C ^a,b   Castellano, G ^a,b   Soronellas, D ^a,b   Bago J R ^c   Blanco, J ^c   Beato, M ^a,b  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c CSIC   (Spain)

Author keywords

Breast cancer; Estrogen receptor; Hormone signaling; Progesterone receptor; T47D; Xenografts

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HISTONE H3; HORMONE RECEPTOR; LIGAND; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROGESTERONE RECEPTOR; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMATIN; CODING; DNA CONTENT; DOWN REGULATION; ENHANCER REGION; ENZYME ACTIVATION; ENZYME ACTIVITY; GEL ELECTROPHORESIS; GENE CONTROL; GENE INDUCTION; GENE MUTATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LOSS OF FUNCTION MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN DEPLETION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; ENZYME ACTIVATION; ESTRADIOL; ESTROGENS; FEMALE; G1 PHASE; HISTONES; HUMANS; MICE; MUTATION; PROGESTINS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RECEPTORS, PROGESTERONE; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; S PHASE; TRANSCRIPTIONAL ACTIVATION;

EID: 84897067023     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.95     Document Type: Article

References (50)

1. Nandi S. Endocrine control of mammarygland development and function in the C3H/ He Crgl mouse. J Natl Cancer Inst 1958; 21: 1039-1063.
2. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery Jr CA et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995; 9: 2266-2278.
3. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69: 963-969.
4. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
5. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998; 90: 37-42.
6. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001; 8: 47-61.
7. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-2589.
8. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA et al. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res 2007; 67: 10582-10591.
9. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003; 22: 7316-7339.
10. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005; 67: 285-308.
11. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851-857.
12. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-317.
13. Blobel GA, Sieff CA, Orkin SH. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Bioly 1995; 15: 3147-3153.
14. Cerillo G, Rees A, Manchanda N, Reilly C, Brogan I, White A et al. The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 1998; 67: 79-88.
15. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998; 17: 2008-2018.
16. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003; 23: 1994-2008.
17. Vicent GP, Ballare C, Nacht AS, Clausell J, Subtil-Rodriguez A, Quiles I et al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell 2006; 24: 367-381.
18. Drobic B, Perez-Cadahia B, Yu J, Kung SK, Davie JR. Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Res 38: 3196-3208.
19. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen-and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998; 17: 4426-4441.
20. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen-and stressactivated protein kinase-1 (MSK1). EMBO J 2003; 22: 1313-1324.
21. Weinstein-Oppenheimer CR, Burrows C, Steelman LS, McCubrey JA. The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol Ther 2002; 1: 256-262.
22. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996; 15: 1292-1300.
23. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001; 8: 269-280.
24. Clarke CL, Roman SD, Graham J, Koga M, Sutherland RL. Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. J Biol Chem 1990; 265: 12694-12700.
25. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006; 24: 261-274.
26. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Pt 1): 95-105.
27. Wilson JE. The molecular weight of rat brain hexokinases. Biochim Biophys Acta 1972; 276: 568-571.
28. Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009; 4: 80-93.
29. Ballare C, Castellano G, Gaveglia L, Althammer S, Gonzalez-Vallinas J, Eyras E et al. Nucleosome driven transcription factor binding and gene regulation. Mol Cell 2013; 49: 67-79.
30. Vicent GP, Nacht AS, Font-Mateu J, Castellano G, Gaveglia L, Ballare C et al. Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev 25: 845-862.
31. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116(Pt 18): 3677-3685.
32. Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005; 438: 1176-1180.
33. Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L, Jacquot S et al. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 1999; 285: 886-891.
34. Thomson S, Mahadevan LC, Clayton AL. MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction. Semin Cell Dev Biol 1999; 10: 205-214.
35. Vicent GP, Zaurin R, Ballare C, Nacht AS, Beato M. Erk signaling and chromatin remodeling in MMTV promoter activation by progestins. Nucl Recept Signal 2009; 7: e008.
36. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271: 20608-20616.
37. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
38. Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W et al. Cyclin E2: a novel CDK2 partner in the late G1 and S-phases of the mammalian cell cycle. Oncogene 1998; 17: 2637-2643.
39. Drobic B, Perez-Cadahia B, Yu J, Kung SK, Davie JR. Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Res 2010; 38: 3196-3208.
40. Wright RH, Castellano G, Bonet J, Le Dily F, Font-Mateu J, Ballare C et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev 2012; 26: 1972-1983.
41. Arthur JS, Fong AL, Dwyer JM, Davare M, Reese E, Obrietan K et al. Mitogen-and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 2004; 24: 4324-4332.
42. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogen-and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002; 22: 2871-2881.
43. Chang S, Iversen L, Kragballe K, Arthur JS, Johansen C. Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model. Cancer Invest 29: 240-245.
44. Sancho M, Diani E, Beato M, Jordan A. Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth. PLoS Genet 2008; 4: e1000227.
45. Subtil-Rodriguez A, Millan-Arino L, Quiles I, Ballare C, Beato M, Jordan A. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol 2008; 28: 3830-3849.
46. Strutt H, Paro R. Mapping DNA target sites of chromatin proteins in vivo by formaldehyde crosslinking. Methods Mol Biol 1999; 119: 455-467.
47. Vicent GP, Zaurin R, Nacht AS, Li A, Font-Mateu J, Le Dily F et al. Two chromatin remodeling activities cooperate during activation of hormone responsive promoters. PLoS Genet 2009; 5: e1000567.
48. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
49. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007; 23: 2700-2707.
50. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.